Sunday 18 October 2026 Export ICCM’s income statement to Excel — free account

IceCure Medical Ltd.

IceCure Medical Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $3.4 million, up 2.67% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 2,068.2%, free cash flow grew 3.88% and total debt fell 64.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

1.06 0.02 +1.92%

Follow ICCM

Alert me

Market cap: $3.6M
P/E: 0.0×
Fwd P/E: −0.2×
Dividend yield: —
F-score: 4/9
Altman Z: −10.01
Beneish M: −2.21
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 37.96%

Capital & Financial Ratios $m

Market Cap 3.56

Revenue 2.70

Net Income (19.59)

Free Cash Flow (20.63)

Net Debt (12.01)

Current Ratio 2.88

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.19)

P/S ratio 0.96

P/B ratio 0.22

Past 5Y EPS Growth —

This Y EPS Growth 25.69%

Next Y EPS Growth 31.59%

Next Y revenue growth (59.00%)

Next 5Y EPS Growth 32.04%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.19%

10-year low 10-year high

P/B against its own 10 years 0.16%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11	8	9	12
Receivables	0	0	0	0
Inventory	2	2	3	3
Other	—	—	—	—
	14	11	13	17

	2023	2024	2025	Q'26
Payables	1	1	1	2
ST’ Debt	—	—	—	—
Other	3	1	1	1
	4	6	5	6

Compound Annual Growth %

	10y	5y	3y
Sales	—	(2.67%)	3.08%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	9.89%	(29.12%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	—	—	—	—
’25	1	—	—	—	3
’24	1	—	—	—	3
’23	1	1	0	—	3
’22	1	1	—	2	3
’21	1	1	1	1	4
’20	—	2	—	2	4

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(4)	—	—	—
’25	(4)	(3)	(10)	—	(15)
’24	(3)	(2)	(8)	—	(13)
’23	(3)	(4)	(10)	—	(13)
’22	(3)	(6)	(10)	(7)	(14)
’21	(2)	(2)	(3)	(6)	(13)
’20	—	(1)	—	(4)	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(4)	—	—	—
’25	(4)	(3)	(10)	—	(15)
’24	(3)	(2)	(8)	—	(13)
’23	(3)	(4)	(10)	—	(13)
’22	(3)	(7)	(11)	(7)	(15)
’21	(2)	(2)	(3)	(6)	(13)
’20	—	(1)	—	(4)	(4)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.80)	—	—	—	—
’25	(1.80)	—	—	—	(7.21)
’24	(2.40)	—	—	—	(9.01)
’23	(2.40)	(0.08)	(0.09)	—	(9.61)
’22	(3.60)	(0.23)	—	(0.21)	(13.81)
’21	(1.99)	(0.05)	(2.70)	(0.10)	(10.51)
’20	—	(0.12)	—	(0.15)	(6.54)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	44.91	44.91	44.91	44.74	5.30	44.15	22.50	15.60	14.40	17.40	Analyst estimates 2026–2028 Powerpack
	High	51.67	44.91	44.91	47.10	73.00	470.98	141.90	46.80	47.10	49.80
People
People	Employees	—	—	—	—	60	64	46	78	66	69
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.06	0.06	0.07	0.04	0.05	0.05
Income, $m
Income, $m	Revenue	1	1	1	2	4	4	3	3	3	3
	Gross margin, %	33.04	23.41	39.44	32.21	63.19	53.04	46.84	40.26	44.09	36.28
	EBT	(3)	(3)	(4)	(5)	(4)	(10)	(17)	(15)	(15)	(15)
	EBT margin, %	(522.82)	(417.15)	(329.70)	(279.72)	(96.43)	(239.13)	(550.34)	(453.76)	(465.45)	(445.61)
	Net income	(3)	0	(4)	(5)	(4)	(10)	(17)	(15)	(15)	(15)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.12	0.11	0.09	3.59	6.78	4.35	2.50	2.12	1.94	1.60
	Earnings	(0.61)	(0.46)	(0.30)	(10.03)	(6.54)	(10.51)	(13.81)	(9.61)	(9.01)	(7.21)
	Cash flow	(0.59)	(0.41)	(0.26)	(4.38)	(6.47)	(13.26)	(11.59)	(8.26)	(7.42)	(6.88)
	Capex	0.00	0.00	0.00	(0.23)	(0.39)	(0.56)	(0.72)	(0.32)	(0.04)	(0.02)
	Free cash flow	(0.59)	(0.41)	(0.26)	(4.61)	(6.86)	(13.82)	(12.32)	(8.57)	(7.46)	(6.90)
	Book value	0.40	(0.04)	0.29	7.26	9.90	28.36	20.62	8.00	4.07	4.28
	Shares, m	5	6	12	0	1	1	1	2	2	2
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	0.00	198.99	697.06	311.69	455.31	19.09	12.98
	P/B	0.00	0.00	0.00	187.39	196.69	106.19	61.97	130.53	7.44	3.88
	EV/Sales	0.00	0.00	0.00	0.00	198.41	691.02	307.06	452.28	16.38	9.75
	EV/FCF	0.00	0.00	0.00	0.00	(131.14)	(216.01)	(54.65)	(62.25)	(1.84)	(1.06)
Cash, $m
Cash, $m	Operating cash flow	(3)	(3)	(3)	(2)	(4)	(13)	(14)	(13)	(13)	(15)
	Capex	0	0	0	0	0	(1)	(1)	0	0	0
	Free cash flow	(3)	(3)	(3)	(2)	(4)	(13)	(15)	(13)	(13)	(15)
Balance, $m
Balance, $m	Working capital	3	0	4	3	6	26	24	10	5	8
	Total debt	—	1	—	0	0	1	0	0	0	0
	Net debt	(3)	(1)	(4)	(6)	(3)	(25)	(24)	(11)	(7)	(9)
	Shareholders’ equity	2	0	3	3	6	27	25	12	7	9
Returns, %
Returns, %	ROA	(124.73)	(173.60)	(82.59)	(72.51)	(42.59)	(46.54)	(54.36)	(62.89)	(105.69)	(113.79)
	ROIC	0.00	0.00	0.00	0.00	(114.34)	(300.57)	(551.50)	(659.11)	0.00	(5,648.95)
	ROE	(354.30)	(311.54)	(227.23)	(136.41)	(83.45)	(60.69)	(64.83)	(77.97)	(160.70)	(188.78)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VNRX VolitionRX Limited	$5.3M	— (loss-making)	— (loss-making)	−1.97% (below 0%: shrinking)	n/m	+18.58% (above 0%: growing)	100.00%	(1,042.39%)	Compare
TRIB Trinity Biotech PLC	$5.1M	— (loss-making)	— (loss-making)	+43.28% (above 0%: growing)	n/m	+75.24% (above 0%: growing)	35.43%	(24.53%)	Compare
VVOS Vivos Therapeutics, Inc.	$4.8M	— (loss-making)	— (loss-making)	+34.90% (above 0%: growing)	n/m	+16.44% (above 0%: growing)	57.31%	(93.63%)	Compare
INBS Intelligent Bio Solutions Inc.	$4.8M	— (loss-making)	— (loss-making)	+51.10% (above 0%: growing)	n/m	−31.59% (below 0%: shrinking)	43.23%	(360.19%)	Compare
ICCM IceCure Medical Ltd.	$3.6M	— (loss-making)	— (loss-making)	−0.69% (below 0%: shrinking)	n/m	+3.88% (above 0%: growing)	32.38%	(466.19%)
BJDX Bluejay Diagnostics, Inc.	$3.5M	0.9×	— (loss-making)	—	n/m	+20.05% (above 0%: growing)	0.00%	0.00%	Compare
ADGM Adagio Medical Holdings, Inc.	$2.8M	— (loss-making)	—	−33.50% (below 0%: shrinking)	n/m	−12.86% (below 0%: shrinking)	0.00%	0.00%	Compare
IVF INVO Fertility, Inc	$2.8M	0.0×	— (loss-making)	+16.73% (above 0%: growing)	n/m	+35.07% (above 0%: growing)	35.06%	(59.28%)	Compare
NXL Nexalin Technology, Inc.	$2.6M	— (loss-making)	— (loss-making)	−82.72% (below 0%: shrinking)	n/m	−97.23% (below 0%: shrinking)	72.95%	(18,420.49%)	Compare
Median of peers	$4.1M	—	—	+16.73%	—	+17.51%	39.33%	(76.46%)

All 149 Medical Devices stocks →

IceCure Medical Ltd. (ICCM) key facts

Strength: IceCure Medical Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $3.4 million, up 2.67% from fiscal 2024.
IceCure Medical Ltd. (ICCM) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ICCM traded at $1.06, a market capitalization of $3.6 million.
Return on equity was −188.8% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −10.01 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.